A5103185770- Psoriasis: Treatment and Pathogenesis
- Autoimmune Bullous Skin Diseases
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Immunodeficiency and Autoimmune Disorders
- Dermatology and Skin Diseases
- Tuberculosis Research and Epidemiology
- Chronic Lymphocytic Leukemia Research
- Clostridium difficile and Clostridium perfringens research
- Platelet Disorders and Treatments
- Gut microbiota and health
- Urticaria and Related Conditions
- Health Systems, Economic Evaluations, Quality of Life
- Inflammatory Bowel Disease
- Rheumatoid Arthritis Research and Therapies
- Eosinophilic Disorders and Syndromes
- Long-Term Effects of COVID-19
- Mast cells and histamine
- Mycobacterium research and diagnosis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Asthma and respiratory diseases
- COVID-19 Clinical Research Studies
West China Hospital of Sichuan University
2021-2024
Sichuan University
2021-2024
Chengdu Women's and Children's Central Hospital
2024
University of Electronic Science and Technology of China
2024
Abbott Fund
2010
Background Adalimumab is effective for moderate to severe chronic plaque psoriasis; however, data regarding retreatment following withdrawal and subsequent relapse are limited. Objectives To evaluate the efficacy safety of adalimumab if interrupted then resumed in patients with psoriasis. Methods Patients a long-term open-label extension study (NCT00195676) who achieved Physician’s Global Assessment (PGA) score ‘Mild’ (2), ‘Minimal’ (1) or ‘Clear’ (0) were withdrawn from monitored PGA...
Previous studies have profiled the gut microbiota among psoriatic patients compared to that healthy individuals. However, a comprehensive understanding of magnitude, direction, and detailed compositional functional profiles remains limited. Additionally, research exploring in context both plaque psoriasis (PsO) arthritis (PsA) is lacking. To assess taxonomic characteristics PsO PsA investigate potential links between disease pathogenesis. We collected fecal samples from 70 (44 26 PsA) 25...
The utilization of biologics in patients with psoriasis latent tuberculosis infection (LTBI) has garnered significant attention. Although the (TB) safety profile second-generation biologics, including secukinumab, been partially confirmed both clinical trials and real-world studies, necessity for prophylactic therapy LTBI prior to administering this class remains a topic controversy. This study enrolled 62 who underwent secukinumab routine TB reexamination. Patients were divided into two...
This study aimed to develop a predictive model based on ultrasound variables which can be used screen patients with psoriasis who are prone progress psoriatic arthritis (PsA) in clinical practice.This is cross-sectional conducted single center from October 2018 November 2020. All subjects (non-PsA group, PsA and control group) underwent an examination their abnormalities were recorded. On the basis of statistical analysis experts' advice, several selected for modelling. We logistic...
This study aims to describe the demographic, clinical, laboratory, and ultrasonic characteristics of patients with psoriatic arthritis (PsA) in Psoriatic Arthritis cohort West China Hospital. In this cross-sectional study, we included diagnosed PsA according Classification Criteria for Arthritis, collected their demographic information, medical histories, treatments, evaluated all domains (skin nail lesions, tenderness, swelling, enthesitis, dactylitis, axial arthritis) related PsA, then...
The tuberculosis (TB) positive conversion rate among psoriasis patients who received biologics has been reported worldwide, particularly in regions with low TB risk. Nonetheless, the TB-related safety of such as adalimumab and secukinumab remains elusive areas high According to World Tuberculosis Report 2021, China is country second highest burden, but data on are also limited. Thus, we performed a retrospective, single-center study profile infection status ratio treated China.Patients were...
A growing number of biologics have recently been approved in China for psoriasis treatment, and some these are eligible Chinese medical insurance, resulting a significant increase the patients receiving biologics. Nevertheless, real-world data on efficacy safety treating moderate-to-severe plaque limited, relevant pharmacoeconomic studies lacking. Therefore, we performed prospective, single-center study to evaluate adalimumab (ADA) secukinumab (SEC) practice. cost-effectiveness analysis...
The objective of this study is to identify the potential risk factors for progression from subclinical clinical psoriatic arthritis (PsA).A retrospective, longitudinal, case-control was conducted at a single hospital, including 25 patients with clinically confirmed PsA in case group and 137 controls without PsA. All both groups had medical history Various baseline covariates were collected all when they status Univariate, multivariate, stratified, interaction analyses employed transiting...
Azathioprine (AZA) is the preferred immunosuppressant for treating pemphigus vulgaris (PV), with discontinuation mainly attributed to hematological adverse events (AE). Reportedly, nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) polymorphisms have been strongly associated thiopurine-induced leukopenia. To investigate AE of low-dose AZA based on NUDT15 genotypes among patients PV, a prospective cohort study was conducted in followed-up first 8 weeks after administration. All...
Background . The global impact of coronavirus 2019 (COVID‐19) has raised concerns about the management psoriasis patients, especially among those using biologics. Methods We conducted a survey‐based research Omicron‐infected (confirmed, probable, and suspected ones) patients in department dermatology, West China Hospital, Sichuan University, from January 9th to 22nd, 2023. collected demographic clinical information (psoriasis‐ COVID‐19‐related) statistics analysis. Results Of 240 enrolled,...